Asunercept

• CAT Number: I042170
• CAS Number: 1450882-18-4
• Purity: ≥95%

Asunercept (Cat No.: I042170) is a recombinant fusion protein designed to inhibit CD95L (Fas ligand), thereby blocking the CD95-mediated apoptotic and inflammatory signaling pathways. It has been investigated primarily for the treatment of glioblastoma and myelodysplastic syndromes, where dysregulated CD95 signaling contributes to disease progression. By preventing immune evasion and resistance to therapy, Asunercept enhances anti-tumor responses and improves clinical outcomes. Its targeted mechanism offers a promising therapeutic approach in cancers and other diseases associated with abnormal cell death regulation.

Reference

[1]. Merz C, et al. Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro. Anticancer Drugs. 2015 Aug;26(7):716-27.
[Content Brief]

[2]. Krendyukov A, et al. Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies. Cancer Manag Res. 2019 Sep 2;11:8095-8100.
[Content Brief]

[3]. Radujkovic A, et al. Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile. Cancers (Basel). 2020 Dec 8;12(12):3683.
[Content Brief]